☆ 4.6 Editorial Material

DIABETIC NEPHROPATHY IN 2014 Improved cardiorenal prognosis in diabetic nephropathy

NATURE REVIEWS NEPHROLOGY (2015)

Journal

NATURE REVIEWS NEPHROLOGY

Volume 11, Issue 2, Pages 68-69

Publisher

NATURE PUBLISHING GROUP

DOI: 10.1038/nrneph.2014.238

Keywords

-

Categories

Urology & Nephrology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

In 2014, key studies in the field of diabetic nephropathy highlighted the importance of albuminuria as a predictor of cardiovascular risk and showed that the incidence of renal and cardiovascular complications is decreasing. Promising efficacy data were obtained with atrasentan, whereas a trial of bardoxolone methyl led to safety concerns.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Biochemistry & Molecular Biology

The Diabetic Cardiorenal Nexus

John A. D'Elia, George P. Bayliss, Larry A. Weinrauch

Summary: Cardiorenal syndrome, the end-stage of heart failure and kidney disease combination, is a serious condition that is influenced by factors such as diabetes, hyperlipidemia, obesity, hypertension, and renal impairment. Current therapy focuses on improving hemodynamic factors destructive to both the heart and kidney, but there have been limited advances in this area.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice

Ander Vergara, Conxita Jacobs-Cacha, Carmen Llorens-Cebria, Alberto Ortiz, Irene Martinez-Diaz, Nerea Martos, Pamela Dominguez-Baez, Mireia Molina Van den Bosch, Sheila Bermejo, Michael Paul Pieper, Begona Benito, Maria Jose Soler

Summary: The combination therapy of empagliflozin, atrasentan, and ramipril shows synergistic cardiorenal protective effects in a type 2 diabetic mouse model. This therapy not only reduces blood glucose and blood pressure, but also prevents further deterioration of kidney function and has positive effects on heart function.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Medicine, General & Internal

Activation of Complement Pathways in Kidney Tissue May Mediate Tubulointerstitial Injury in Diabetic Nephropathy

Shimin Jiang, Yuanyuan Jiao, Guming Zou, Hongmei Gao, Li Zhuo, Wenge Li

Summary: This study found that complement-related genes are linked to the mechanism underlying tubulointerstitial injury in diabetic nephropathy (DN). The deposits of C3 and C1q in kidney tissues are independently associated with the renal outcome in DN, and higher expression of complement factors increases the risk of progression to kidney failure in DN patients.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Article Urology & Nephrology

Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial

David Lam, Girish N. Nadkarni, Gohar Mosoyan, Bruce Neal, Kenneth W. Mahaffey, Norman Rosenthal, Michael K. Hansen, Hiddo J. L. Heerspink, Fergus Fleming, Steven G. Coca

Summary: KidneyIntelX successfully stratified the risk of DKD progression and showed that canagliflozin treatment reduced the risk score and was associated with future kidney outcomes. Changes in the KidneyIntelX score were independently associated with the risk of DKD progression.

AMERICAN JOURNAL OF NEPHROLOGY (2022)

Add to Collection

Article Immunology

Complement Deposition Predicts Worsening Kidney Function and Underlines the Clinical Significance of the 2010 Renal Pathology Society Classification of Diabetic Nephropathy

Shimin Jiang, Dingxin Di, Yuanyuan Jiao, Guming Zou, Hongmei Gao, Wenge Li

Summary: The study demonstrates the correlation between glomerular C3 deposits and RPS DN classification, as well as their combined deleterious effects on kidney function. Patients with C3 deposition had a higher risk of adverse kidney outcomes.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Salivary Glycopatterns as Potential Non-Invasive Biomarkers for Diagnosing and Reflecting Severity and Prognosis of Diabetic Nephropathy

Qiuxia Han, Xiaochen Wang, Xiaonan Ding, Jing Hao, Qi Li, Jifeng Wang, Hanjie Yu, Zhen Tang, Fuquan Yang, Guangyan Cai, Dong Zhang, Hanyu Zhu

Summary: Salivary glycopatterns could be used to differentiate between diabetic nephropathy (DN) and non-diabetic renal disease (NDRD). Levels of AAL, LEL, LCA, VVA, and NPA were correlated with DN severity, while levels of LEL and LCA could indicate the prognosis of DN.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Identification of Key Candidate Genes and Chemical Perturbagens in Diabetic Kidney Disease Using Integrated Bioinformatics Analysis

Zhuo Gao, S. Aishwarya, Xiao-mei Li, Xin-lun Li, Li-na Sui

Summary: This study identified potential key genes and pathways involved in the progression of DKD through integrated bioinformatics analysis. Several differentially expressed genes with roles in DKD progression were identified, along with two drugs that have a validated role in reversing the observed differential gene expression patterns.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

QiDiTangShen granules modulated the gut microbiome composition and improved bile acid profiles in a mouse model of diabetic nephropathy

Huili Wei, Lin Wang, Zhichao An, Huidi Xie, Weijing Liu, Qing Du, Yan Guo, Xi Wu, Sicheng Li, Yang Shi, Xianhui Zhang, Hongfang Liu

Summary: QiDiTangShen granules (QDTS) have been shown to significantly alleviate renal injuries in mice with diabetic nephropathy (DN), reducing urinary albumin excretion and attenuating pathological kidney damage. QDTS altered gut microbiota composition and decreased serum levels of bile acids associated with the activation of farnesoid X receptor (FXR). However, the specific mechanism for QDTS reno-protection in DN remains to be further studied.

BIOMEDICINE & PHARMACOTHERAPY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial

James L. Januzzi, Reza Mohebi, Yuxi Liu, Naveed Sattar, Hiddo J. L. Heerspink, Eshetu Tefera, Muthiah Vaduganathan, Javed Butler, Yshai Yavin, Jingwei Li, Carol A. Pollock, Vlado Perkovic, Bruce Neal, Michael K. Hansen

Summary: Multiple cardiorenal stress biomarkers are strongly prognostic in people with type 2 diabetes and albuminuria. Canagliflozin modestly reduced the longitudinal trajectory of rise in each biomarker. Change in the biomarker level in addition to the baseline level augments the primary outcome prediction.

CIRCULATION (2023)

Add to Collection

Article Endocrinology & Metabolism

Aspartate aminotransferase to alanine aminotransferase ratio and the risk of diabetic nephropathy progression in patients with type 2 diabetes mellitus: A biopsy-based study

Yucheng Wu, Fang Liu

Summary: This study aimed to investigate the relationship between baseline serum aspartate aminotransferase (AST) to alanine amino-transferase (ALT) ratio (AAR) and clinicopathological features and renal outcome in patients with type 2 diabetes mellitus (T2DM) and biopsy-confirmed diabetic nephropathy (DN). The study found that high AAR was associated with more severe renal pathological lesions and worse renal function in patients with T2DM and DN.

JOURNAL OF DIABETES AND ITS COMPLICATIONS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome

Konrad Urbanek, Donato Cappetta, Gabriella Bellocchio, Maria Antonietta Coppola, Paola Imbrici, Marialucia Telesca, Maria Donniacuo, Maria Antonietta Riemma, Elena Mele, Eleonora Cianflone, Silvio Naviglio, Elena Conte, Giulia Maria Camerino, Marco Mele, Mariarosaria Bucci, Giuseppe Castaldo, Annamaria De Luca, Francesco Rossi, Liberato Berrino, Antonella Liantonio, Antonella De Angelis

Summary: Cardiorenal syndrome is a range of disorders involving heart and kidney dysfunction, with common risk factors such as hypertension and diabetes. Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been shown to reduce the risk of heart failure and improve renal endpoints in both diabetic and non-diabetic patients. In a non-diabetic model of cardiorenal syndrome, dapagliflozin provides renal protection by modulating inflammatory response, endothelial activation, fibrosis, oxidative stress, local RAAS, and ion channels.

PHARMACOLOGICAL RESEARCH (2023)

Add to Collection

Review Endocrinology & Metabolism

Cardiorenal Protection in Diabetic Kidney

Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z. Cherney

Summary: There have been significant advancements in the management of diabetic kidney disease over the past 5 years, including the use of GLP-1 RA, SGLT2 inhibitors, and MRAs. These medications not only benefit glycemic control, but also extend to cardiovascular and kidney outcomes. With patients with type 2 diabetes being at significant risk of cardiovascular disease and progression of chronic kidney disease, the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA, and MRAs is now being considered for heart and kidney protection.

ENDOCRINOLOGY AND METABOLISM (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Tetrahydrobiopterin (BH4) Supplementation Prevents the Cardiorenal Effects of Diabetes in Mice by Reducing Oxidative Stress, Inflammation and Fibrosis

Ulises Novoa, Karen Soto, Cristian Valdes, Jorge Villasenor, Adriana Treuer, Daniel R. Gonzalez

Summary: This study found that treatment with BH4 can prevent the development of diabetic cardiomyopathy and nephropathy. BH4 treatment reduced cardiac hypertrophy and fibrosis, as well as glomerular hypertrophy and fibrosis. These results suggest that BH4-based treatment may ameliorate the cardiorenal effects of diabetes by restoring the nitroso-redox balance.

BIOMEDICINES (2022)

Add to Collection

Article Environmental Sciences

Supplementation with selenium nanoparticles alleviates diabetic nephropathy during pregnancy in the diabetic female rats

Ibrahim M. Alhazza, Hossam Ebaid, Mohamed S. Omar, Iftekhar Hassan, Mohamed A. Habila, Jameel Al-Tamimi, Mohamed Sheikh

Summary: The study found that selenium nanoparticles (SeNPs) have a protective effect against kidney injury in streptozocin-induced diabetic rats, improving symptoms such as polyuria, delayed gestation, and abnormal pancreatic beta-cells.

ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Relationship between Diabetic Nephropathy and Development of Diabetic Macular Edema in Addition to Diabetic Retinopathy

Yukihisa Suzuki, Motohiro Kiyosawa

Summary: This study examined the relationship between diabetic retinopathy (DR) and systemic factors in 261 patients with type 2 diabetes. Logistic regression analyses revealed that the duration of diabetes, average and highest HbA1c levels, and grade of diabetic nephropathy (DN) significantly correlated with the development of DR. Additionally, the severity of DR was significantly correlated with the duration of diabetes, average HbA1c level, and severity of DN. Logistic regression analyses also showed a significant correlation between the development of diabetic macular edema (DME) and the grade of DN. DN grade is associated with the development of DR and DME, and decreased renal function predicts the onset of DR.

BIOMEDICINES (2023)

Add to Collection

Article Endocrinology & Metabolism

In vivo molecular imaging of cardiac angiogenesis in persons with and without type 2 diabetes: A cross-sectional 68 Ga-RGD-PET study

Jens Christian Laursen, Ida Kirstine Bull Rasmussen, Emilie Hein Zobel, Philip Hasbak, Lene Holmvang, Christian Stevns Hansen, Bernt Johan von Scholten, Marie Frimodt-Moller, Peter Rossing, Tine Willum Hansen, Andreas Kjaer, Rasmus Sejersten Ripa

Summary: Cardiac angiogenesis assessed by Ga-68-RGD PET was similar in type 2 diabetes and non-diabetic controls, and was not associated with kidney function or other risk factors.

DIABETIC MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD

Meir Schechter, Niels Jongs, Glenn M. Chertow, Ofri Mosenzon, John J. McMurray, Ricardo Correa-Rotter, Peter Rossing, Anna Maria Langkilde, C. David Sjostrom, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink

Summary: This study aimed to determine the effects of dapagliflozin on hospitalizations in patients with chronic kidney disease (CKD). The results showed that dapagliflozin reduced the risk of hospitalization for any cause in patients with CKD, regardless of whether they had type 2 diabetes or not.

ANNALS OF INTERNAL MEDICINE (2023)

Add to Collection

Article Endocrinology & Metabolism

Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial

Viktor Rotbain Curovic, Niels Jongs, Marjolein Y. A. M. Kroonen, Emilie H. Zobel, Tine W. Hansen, Taha Sen, Gozewijn D. Laverman, Adriaan Kooy, Frederik Persson, Peter Rossing, Hiddo J. L. Heerspink

Summary: This randomized crossover trial found significant variation in participants' responses to different drug classes in terms of urinary albumin to creatinine ratio (UACR) reduction. The results suggest that systematic rotation through different drug classes can overcome resistance to RAS inhibitors.

DIABETES CARE (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Oliver Schnell, Tadej Battelino, Richard Bergenstal, Andreas L. Birkenfeld, Antonio Ceriello, Alice Cheng, Melanie Davies, Steve Edelman, Thomas Forst, Francesco Giorgino, Jennifer Green, Per-Henrik Groop, Samy Hadjadj, Hiddo J. L. Heerspink, Marcus Hompesch, Baruch Izthak, Linong Ji, Naresh Kanumilli, Boris Mankovsky, Chantal Mathieu, Martin Miszon, Reem Mustafa, Michael Nauck, Roberto Pecoits-Filho, Jeremy Pettus, Kari Ranta, Helena W. Rodbard, Peter Rossing, Lars Ryden, Petra-Maria Schumm-Draeger, Scott D. Solomon, Jan Skrha, Pinar Topsever, Tina Vilsboll, John Wilding, Eberhard Standl

Summary: The 8th Cardiovascular Outcome Trial (CVOT) Summit focused on discussing and exchanging recently completed outcomes trials and key trials important to the cardiovascular field. Topics included the results of trials on heart failure, chronic kidney disease, and obesity, as well as consensus recommendations and guideline updates on diabetes and CKD management. The impact of cardiovascular outcomes on liver disease trials and the role of real-world evidence in confirming trial outcomes were also discussed. The 9th CVOT Summit will be held virtually on November 23-24, 2023.

CARDIOVASCULAR DIABETOLOGY (2023)

Add to Collection

Article Urology & Nephrology

Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes A FIDELITY Subgroup Analysis

Pantelis Sarafidis, Rajiv Agarwal, Bertram Pitt, Christoph Wanner, Gerasimos Filippatos, John R. Boletis, Katherine M. Tuttle, Luis Ruilope, Peter Rossing, Robert D. Toto, Stefan Anker, Zhi-Hong Liu, Amer Joseph, Christiane Ahlers, Meike Brinker, Robert Lawatscheck, George Bakris

Summary: Finerenone has shown to improve heart-kidney outcomes in patients with stage 4 CKD and type 2 diabetes. However, the effects on the composite kidney outcome were inconsistent over time.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Add to Collection

Article Endocrinology & Metabolism

Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease

Niels Sondergaard Heinrich, Rune Ploegstra Pedersen, Mark Bitsch Vestergaard, Ulrich Lindberg, Ulrik Bjorn Andersen, Bryan Haddock, Tine Willum Hansen, Alessia Fornoni, Henrik Bo Wiberg Larsson, Peter Rossing

Summary: This study investigated the effects of ezetimibe on the urine albumin creatinine ratio (UACR) and kidney parenchyma fat content (kidney-PF) in individuals with type 2 diabetes and early chronic kidney disease. The results showed that ezetimibe did not significantly reduce UACR or kidney-PF overall, but it did reduce kidney-PF in participants with high baseline levels.

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Article Genetics & Heredity

Differential Methylation of Telomere-Related Genes Is Associated with Kidney Disease in Individuals with Type 1 Diabetes

Claire Hill, Seamus M. Duffy, Laura Kettyle, Liane McGlynn, Niina M. Sandholm, Rany Salem, Alex J. Thompson, Elizabeth Swan, Jill Kilner, Peter G. Rossing, Paul Shiels, Maria Lajer, Per-Henrik Groop, Alexander Peter Maxwell, Amy Jayne McKnight, GENIE Consortium

Summary: Diabetic kidney disease (DKD) is a major global health problem characterized by accelerated aging. This study explored features affecting telomere biology and methylation dysregulation in DKD using multi-omics approaches, which may provide useful biomarkers or therapeutic targets.

GENES (2023)

Add to Collection

Editorial Material Endocrinology & Metabolism

People with type 1 diabetes and chronic kidney disease urgently need newtherapies: a call for action

Hiddo J. L. Heerspink, David Z. Cherney, Per-Henrik Groop, Chantal Matthieu, Peter Rossing, Katherine R. Tuttle, Janet B. McGill

LANCET DIABETES & ENDOCRINOLOGY (2023)

Add to Collection

Article Urology & Nephrology

Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis

Daisuke Koya, Stefan D. Anker, Luis M. Ruilope, Peter Rossing, Zhihong Liu, Byung Wan Lee, Chien-Te Lee, Charlie Scott, Peter Kolkhof, Robert Lawatscheck, Lili Wang, Amer Joseph, Bertram Pitt

Summary: This study found that finerenone significantly improved cardiorenal outcomes in Asian patients, with similar benefits seen in non-Asian patients as well. The safety profile of finerenone was consistent across subgroups.

AMERICAN JOURNAL OF NEPHROLOGY (2023)

Add to Collection

Article Urology & Nephrology

Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in CKD

Katherine R. Tuttle, Peter Rossing, Sibylle J. Hauske, Lisa Cronin, Joanna Hussain, Dick de Zeeuw, Hiddo J. L. Heerspink

Summary: This study aimed to evaluate the efficacy and safety of BI 690517 and determine if it has an additive kidney protection effect in CKD patients already treated with a renin-angiotensin system inhibitor. The results will inform dose selection for further clinical development.

AMERICAN JOURNAL OF NEPHROLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis

Peter Rossing, Stephen C. Bain, Heidrun Bosch-Traberg, Ekaterina Sokareva, Hiddo J. L. Heerspink, Soren Rasmussen, Linda G. Mellbin

Summary: This post hoc analysis investigated the effects of glucose-lowering treatment (semaglutide) on cardiovascular risk in patients with type 2 diabetes, and the association with baseline kidney parameters. The results showed that individuals with reduced kidney function and increased albuminuria had a higher risk of cardiovascular events. Semaglutide consistently reduced the risk of cardiovascular events in all subgroups, regardless of kidney function.

CARDIOVASCULAR DIABETOLOGY (2023)

Add to Collection

Review Endocrinology & Metabolism

Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes

Vikas S. Sridhar, Christine P. Limonte, Per-Henrik Groop, Hiddo J. L. Heerspink, Richard E. Pratley, Peter Rossing, Jay S. Skyler, David Z. I. Cherney

Summary: The current management of CKD in type 1 diabetes focuses on blood sugar control, inhibiting the renin-angiotensin system and optimizing risk factors. However, individuals with type 1 diabetes and CKD still face elevated risks for kidney and cardiovascular events. Novel therapies used in type 2 diabetes, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists, have shown potential kidney and heart protection. Applying these therapies to individuals with type 1 diabetes for the prevention of CKD is of great importance.

DIABETOLOGIA (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials

Asger Wretlind, Viktor Rotbain Curovic, Andressa de Zawadzki, Tommi Suvitaival, Jin Xu, Emilie Hein Zobel, Bernt Johan von Scholten, Rasmus Sejersten Ripa, Andreas Kjaer, Tine Willum Hansen, Tina Vilsboll, Henrik Vestergaard, Peter Rossing, Cristina Legido-Quigley

Summary: Treatment with liraglutide can reduce the levels of C16 ceramide and C24:1 ceramide, which are associated with cardiovascular disease (CVD) risk.

LIPIDS IN HEALTH AND DISEASE (2023)

Add to Collection

Article Transplantation

Urinary peptide analysis to predict the response to blood pressure medication

Mayra Alejandra Jaimes Campos, Emmanouil Mavrogeorgis, Agnieszka Latosinska, Susanne Eder, Lukas Buchwinkler, Harald Mischak, Justyna Siwy, Peter Rossing, Gert Mayer, Joachim Jankowski

Summary: Proteome analysis of urinary peptides may predict the response to treatment with RAS inhibitors and avoid progression of diabetic kidney disease.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Add to Collection

Article Neurosciences

Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy

Mark B. Vestergaard, Jens Christian Laursen, Niels Sondergaard Heinrich, Peter Rossing, Tine Willum Hansen, Henrik B. W. Larsson

Summary: This study found brain alterations and atrophy in patients with T1D, possibly due to complications of diabetes affecting cerebral vascular and glycolytic functions.

FRONTIERS IN NEUROSCIENCE (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.